Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | PKLR | P30613 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.55 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27922521 | 0.85 | KDM4E (0.67) | PKMPKLRMEN1KMT2AALDH1A1 | |
| SCHEMBL30030626 | 0.83 | PKM (0.84) | PKMPKLRMEN1KMT2AALDH1A1 | |
| SCHEMBL7855977 | 0.79 | MEN1 (0.70) | PKMPKLRMEN1KMT2AALDH1A1 | |
| SCHEMBL7674750 | 0.77 | POLB (0.59) | PKMPKLRMEN1KMT2AALDH1A1 | |
| SCHEMBL4215800 | 0.76 | BCL2 (0.59) | SSTR4SSTR3ALDH1A1MAPTBCL2 | |
| SCHEMBL30648199 | 0.76 | MEN1 (1.00) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL553605 | 0.76 | MEN1 (1.00) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL21399633 | 0.76 | GPR84 (0.68) | MEN1KMT2ASSTR4SSTR3MAPT | |
| SCHEMBL21399641 | 0.76 | MEN1 (0.68) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL21399587 | 0.76 | MEN1 (0.68) | MEN1KMT2ASSTR4SSTR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2006034390-A2 | INHIBITORS OF 15-LIPOXYGENASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063823-A1 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1135124-B1 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | INST FOR PHARM DISCOVERY INC (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1030701-C | Indole derivatives and process for production thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-01-17 | — | — | CN | disclosed |
| US-5312829-A | Testosterone 5alpha-reductase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| US-5212320-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| CN-1056685-A | Indole derivatives and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-12-04 | — | — | CN | disclosed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063823-A1 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | PTGIS, MMP15, IL15 | PKM 3976/4885PKLR 329/4885MEN1 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.